Jiayin cashes in on China’s efforts to boost consumer spending
The fintech lender’s revenue from its main business jumped in last year’s fourth quarter as China rolled out a series of measures to stimulate its economy Key Takeaways: Jiayin’s revenue…
BRIEF: FinVolution profit jumps on gains in loan facilitation, international revenue
FinVolution Group (FINV.US) reported on Monday its revenue rose 7.2% year-on-year in last year’s fourth quarter to 3.46 billion yuan ($478 million), while its net profit jumped 29% to 681…
Auditor drama casts unflattering light on Lufax at already-difficult time
The online loan facilitator moved to fire PwC after the accountant raised a red flag over some related-party transactions Key Takeaways: Lufax’s board has proposed terminating PwC as its external…
FinVolution finds riches, achieves growth despite headwinds, in global markets
The fintech lender launched its international expansion in 2018, and plans to enter more countries this year and next Key Takeaways: FinVolution has accelerated its overseas expansion as demand slows…
Noah’s development arc takes overseas turn as life at home only gets tougher
The asset management firm’s overseas revenue growth partially offset a decline in its core domestic business in the third quarter Key Takeaways: Noah’s overseas revenue grew 29% year-on-year in the…
BRIEF: FinVolution revenue rises as global contribution grows
Online lender FinVolution Group (FINV.US) said on Monday its revenue rose 2.5% in the third quarter to 3.28 billion yuan ($453 million) year-on-year, as weakness in its home China market…
Yiren finds big returns in small-loan focus, even as headwinds swirl
The online loan facilitator’s revenue from its main financial services business jumped 46% in the second quarter, as it also sharply raised its bad-loan provisions Key Takeaways: Small revolving loans,…
Recent Articles
RELATED ARTICLES
-
Cash-strapped Mirxes looks for lifeline in blood-based cancer detection
-
Everest Medicines drives growth with AI-powered mRNA pipeline
1952.HK
-
A blockbuster cancer drug? TYK’s claims go under the microscope
2410.HK
-
NEWS WRAP: Hutchmed sells non-core asset to focus on cancer treatment
0013.HK HCM.US
- Cancer drug maker Genfleet joins Hong Kong IPO influx
-
Cango’s latest pivot uncovers gold in bitcoin mining
CANG.US
-
Everest Medicines eyes mRNA tumor vaccines as drug valuations rebound
1952.HK
